Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial.
PD MED Collaborative Group*
Background Whether initial treatment for Parkinson’s disease should consist of levodopa, dopamine agonists, or monoamine oxidase type B inhibitors (MAOBI) is uncertain. We aimed to establish which of these three classes of drug, as initial treatment, provides the most effective long-term control of symptoms and best quality of life for people with early Parkinson’s disease. PDMED
June 11, 2014 http://dx.doi.org/10.1016/ S0140-6736(14)60683-8
*Members listed at end of paper
PD MED Trial Office, Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, Robert Aitken Institute for Clinical Research, University of Birmingham, Birmingham
B15 2TT, UK PDfirstname.lastname@example.org